Conclusions: Ultrasound-guided percutaneous kidney biopsy is a relatively safe, well-tolerated procedure in the HIVinfected population. HIV-infected individuals who are co-infected with hepatitis C seem to be at greatest risk.
H IV-infected patients with kidney disease often require percutaneous kidney biopsy to aid in diagnosis and management of the underlying kidney disease (1) . Although relatively simple to perform, ultrasound-guided biopsies do entail known risks. The risks of percutaneous ultrasound-guided kidney biopsy have been well-described in the general population (2, 3) , but the specific risks in the HIVinfected population are relatively unknown.
Bleeding is the most common and serious of biopsy-related complications, which also include infection, pain, inadvertent injury to other organs, and rarely death. Several studies have assessed predictors of bleeding complications of ultrasoundguided biopsy in the general population (4, 5) , but, to date, the HIV-infected population has not been examined separately. Coagulopathies, thrombocytopenia, and endothelial dysfunction have been reported to exist at a higher frequency in HIVinfected patients (6 -8) and may modify bleeding risk. As such, accurate data on the rate of biopsy complications in this population are important for the informed consent process; therefore, in this study, we assessed the risk for complication in HIV-positive patients as compared with HIV-negative patients who were undergoing real-time ultrasound-guided percutaneous kidney biopsy at a single tertiary care academic center.
Materials and Methods

Study Design and Population
A single-center, retrospective, case-control study of 1116 ultrasoundguided percutaneous native kidney biopsies that were performed on 1024 adult patients at the Johns Hopkins Hospital between February 1, 1995, and December 31, 2007, was performed. All patients who were Ն18 yr of age and underwent ultrasound-guided percutaneous kidney biopsy during this time frame were included. Patients did not undergo biopsy when they had uncontrolled hypertension (systolic BP Ͼ160 mmHg or diastolic BP Ͼ90 mmHg), international normalized ratio Ն1.3 s or partial thromboplastin time Ն42.1 s, platelet count Ͻ50,000 cells/ mm 3 , aspirin or clopidogrel use in the preceding 5 d, or evidence of hemodynamic instability at the time of the procedure. All patients had preprocedure coagulation studies. Bleeding times were not measured for any patient. This study was approved by the institutional review board of the Johns Hopkins University School of Medicine.
Outcomes
The primary outcome was any minor or major complication. Minor complication was defined as (1) hematoma Ն4 cm in size or described as "moderate" or "large" on imaging reports, (2) voiding difficulty that required temporary urethral catheterization, or (3) gross hematuria. Routine postbiopsy imaging was not performed on all patients. Imaging was performed only in the context of clinical symptoms (abdominal or flank pain) or drop in hematocrit that was worrisome for bleeding. Major complication was defined as biopsy-associated bleeding that required (1) packed red blood cell transfusion, angiography, or surgery; (2) hypotension that required transfer to a higher level of nursing care or need for intravenous fluid or vasopressor support; or (3) death. Secondary outcomes were the subgroups of minor and major complications.
Exposure Variables
Clinical, demographic, and laboratory data were abstracted from the electronic patient record. Data on prebiopsy blood urea nitrogen (BUN), creatinine, platelet count, and hematocrit were missing for 25, 19, 22, and 29 patients, respectively. For those with major complications, there were no missing hematocrit or platelet data and only one patient lacked a BUN and creatinine value. The primary predictor of interest was HIV infection, and the remaining predefined predictors of interest included age, prebiopsy mean arterial pressure, prebiopsy hematocrit Ͻ30%, prebiopsy platelet count (per 10,000-cells/mm 3 
Biopsy Technique
Informed written consent was obtained before kidney biopsy. The biopsy technique remained essentially unchanged during the period of this study. Biopsies were performed by attending nephrologists or by nephrology fellows under direct attending supervision. Semiautomated 18-G needles were used for all biopsies, and experienced radiology technicians provided real-time ultrasound guidance. A needleguide device attached to the ultrasound probe was used in 931 (83.4%) of the biopsies. Typically, two or three cores were obtained per biopsy. After biopsy, patients were monitored for signs of complication for at least 23 h, with frequent vital sign assessment, repeat hemoglobin measurement the next morning in most cases, and follow-up imaging when concern for a bleeding complication existed. Patients remained on bed rest for at least 6 h. Follow-up care was determined by the attending nephrologist, on the basis of the patient's clinical status and final renal pathologic diagnosis.
Statistical Analysis
Baseline characteristics between biopsies with and without a complication, as well as between biopsies from HIV-infected and non-HIVinfected patients, were compared by t, 2 , and Wilcoxon rank-sum tests, as appropriate. Univariate logistic regression was used to determine the risk for a biopsy-related complication associated with a predefined predictor of interest. To account for missing hepatitis C status in HIVnegative individuals, hepatitis C status was imputed by univariate imputation sampling using characteristics of the HIV-negative participants with known hepatitis C status (10) . Imputed hepatitis C data were used in regression analyses. Sensitivity analyses for the association of hepatitis C were also performed by analyzing the association with postbiopsy complication after assigning all missing data to either infected or noninfected. Because of the small sample size, multivariable adjustment was limited to five covariates (HIV infection, hepatitis C, prebiopsy hematocrit Ͻ30%, prebiopsy platelet count, and eGFR Ͻ30 ml/min per 1.73 m 2 ) identified as potential confounders in the univariate analysis. The presence of effect modification was assessed in variables of interest identified from the primary analysis. Robust variances were calculated to account for clustering that may occur on the basis of the biopsy attending of record. This study had 90% power for a detectable odds ratio (OR) of 2.0 for any complication in HIV-infected versus non-HIV-infected patients. In the primary analysis, the P value of the association was Bonferroni-corrected for seven comparisons, with an unadjusted P Յ 0.003 considered statistically significant to permit a Bonferroni-corrected P Յ 0.05 after adjustment for multiple comparisons. Unadjusted P values are reported except where indicated. Statistical analyses were performed using the Stata 9.2 statistical package (Stata Corp., College Station, TX).
Results
Baseline Characteristics
A total of 1116 (HIV-infected ϭ 243 [21.8%]; non-HIV-infected ϭ 873 [78.2%]) ultrasound-guided percutaneous kidney biopsies were performed on 1024 individuals. Baseline characteristics of the cohort are presented in Table 1 . Of the 1116 biopsies, 77 (6.9%) individuals had two biopsies, 13 (1.2%) had three biopsies, and two (0.2%) had four biopsies. Of these 92 repeat biopsies, 12 (13.0%) were from HIV-infected individuals. Because none of the individuals who underwent repeat biopsy experienced more than one complication, the data are based on a denominator of 1116. HIV-infected patients were more likely to be black (89.3 versus 48.6%; P Ͻ 0.001), male (63.8 versus 38.1%; P Ͻ 0.001), and hepatitis C positive (54.3 versus 5.6%; P Ͻ 0.001) and to have a lower median eGFR (29.2 versus 45.7 ml/min per 1.73 m 2 ; P Ͻ 0.001) at the time of biopsy. HIVinfected patients were also more likely to have baseline hypertension (56.4 versus 19.9%; P Ͻ 0.001) and to have a slightly lower prebiopsy hematocrit (32.4 versus 33.6%; P ϭ 0.006) and median platelet count (207,500 versus 259,900 cells/mm 3 ; P Ͻ 0.001). Hepatitis C status was known for 100% of the HIVpositive individuals and 86.7% of HIV-negative individuals. After imputation of the missing hepatitis C values, a status was assigned to 98.6% of HIV-negative individuals, with 5.0% (n ϭ 44) being hepatitis C positive as compared with 4.8% (n ϭ 42) before imputation. Nonimputed data are presented in Table 1 .
Postbiopsy Complications
The proportion of patients who experienced any complication (8.6 versus 7.2%; P ϭ 0.5), a minor (5.4 versus 4.6%; P ϭ 0.6), or a major complication (3.3 versus 2.6%; P ϭ 0.7) did not differ significantly between the HIV-infected and non-HIV-infected patients, respectively. Of those who had multiple biopsies, Table 1 . 
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Columns may not sum to total due to missing data. IQR, interquartile range. a eGFR Ͼ60 ml/min per 1.73 m 2 expressed as 60.
none experienced a complication twice. The overall complication rate in the entire population did not differ by the use of a guide (8.1% with a guide versus 4.9% without a guide; P ϭ 0.2). Table 2 details the individual major complications that occurred in the HIV-infected group. Only one patient required angiography, and three patients who required blood transfusion also experienced hemodynamic instability. Of the eight patients with major complications, three were discharged within 24 h and four in Ͻ1 wk. Seven (88%) of these eight patients were hepatitis C positive. Eleven (84.6%) of 13 HIVinfected patients with minor complications were hepatitis C positive. Among non-HIV-infected patients, two (8.7%) of 23 patients with major complications and two (5%) of 40 with minor complications were hepatitis C infected. A comparison of the types of major complication stratified by HIV status are reported in Table 3 . Of note, there were no deaths as a result of kidney biopsy in this cohort.
The associations of a priori selected predictors of complication are reported in Table 4 . HIV positivity was associated with a nonstatistically significant OR of 1.28 (95% confidence interval [CI] 0.95 to 1.73; P ϭ 0.1) for any complication. In the entire cohort, biopsies from individuals who were positive for hepatitis C infection had a 2.08 (95% CI 1.47 to 2.93) increased odds of any complication relative to individuals who were not infected with hepatitis C. This association remained statistically significant (P Ͻ 0.001) after Bonferroni correction. A consistent, statistically significant relationship was also seen for the associations of hepatitis C infection with the subgroups of minor and major complications. Each decrease of 10,000 cells/mm 3 in the prebiopsy platelet count was also associated with a statistically significant OR of 1.05 (95% CI 1.02 to 1.08) for any complication, and this remained statistically significant after Bonferroni correction (P ϭ 0.01). No other robust associations were seen between the predefined covariates and any compli- Given the possibility for biologic interplay between hepatitis C and HIV co-infection, the association of hepatitis C with postbiopsy complication was examined after stratification by HIV status (Figure 1 ). Hepatitis C/HIV co-infection was associated with a 5.71 (95% CI 1.89 to 17.2; P ϭ 0.002) increased odds of any complication as compared with 1.27 (95% CI 0.73 to 2.19; P ϭ 0.4) in hepatitis C-positive/HIV-negative individuals (P ϭ 0.006 for interaction). Similarly, prebiopsy hematocrit Ͻ30% in HIV-infected individuals was associated with a 2.69 (95% CI 1.57 to 4.62; P Ͻ 0.001) increased odds of any complication as compared with a 1.08 (95% CI 0.68 to 1.71; P ϭ 0.7) increased odds in HIV-negative individuals (P ϭ 0.02 for interaction). When the outcome of major complication was examined, prebiopsy hematocrit Ͻ30% in HIV-infected individuals was associated with a 2.97 (95% CI 1.56 to 5.65; P ϭ 0.001) increased odds of complication as compared with a 15.3 (95% To confirm the validity of the association between imputed hepatitis C data and the risk for complication, we performed sensitivity analyses using the original data, as well as after assigning all missing values to either a hepatitis C-positive or -negative status. Using the original, nonimputed data, the OR of any complication for a hepatitis C-positive individual was 2.07 (95% CI 1.42 to 3.02; P Ͻ 0.001) relative to a hepatitis C-negative individual. After assigning all missing data as hepatitis C positive, the OR of any complication was 1.56 (95% CI 1.19 to 2.06; P ϭ 0.001), and after assigning all missing data as hepatitis C negative, the OR for any complication was 2.11 (95% CI 1.50 to 2.96; P Ͻ 0.001). Imputation for missing BUN, creatinine, hematocrit, and platelet count data did not change the results of the analysis (data not shown).
Comparing hepatitis C-co-infected HIV-positive patients with HIV-positive patients without hepatitis C revealed no significant difference in hematocrit, platelet count, BUN, creatinine, eGFR, CD4 count, HIV viral load, gender, race, or presence of diabetes or hypertension. Co-infected patients were older (mean age 46.0 versus 43.7 yr; P ϭ 0.04). Not surprising, the key difference in these populations was the high proportion of illicit drug use in the co-infected group (86.8 versus 13.2%; P Ͻ 0.001).
Discussion
This study comprises the largest series of HIV-infected patients who underwent percutaneous ultrasound-guided kidney biopsy to date. No previous study has evaluated biopsy complication rates in this population. These data demonstrate that ultrasound-guided percutaneous kidney biopsy is well tolerated in this population, with complication rates in hepatitis C-negative/HIV-positive individuals comparable to those in the non-HIV-infected population. The major complication rates between 2.6 and 3.3% are consistent with those seen in previous studies. In a cohort study of 750 adult patients who underwent 1%, respectively were observed. Definitions of major complications were similar across these previous studies, whereas definitions for minor complications varied widely. It is difficult to compare directly minor complication rates in the face of this variability in definition.
HIV infection alone was not associated with the development of postbiopsy complications. In the assessment of predictors, we found hepatitis C to be a positive predictor of increased bleeding complications, with hepatitis C/HIV co-infection being the strongest predictor. To our knowledge, this has not been previously described in studies of risk factors for complication in percutaneous kidney biopsy. Sterling et al. (12) evaluated percutaneous liver biopsy safety in 29 male adults with hemophilia with hepatitis C infection, 44% of whom had HIV coinfection. There were no complications in any patient, regardless of HIV status, although the sample size was small.
HIV co-infection is not known to increase independently the risk for bleeding in patients with hepatitis C, beyond accelerating the progression of underlying liver disease with resultant coagulopathy (13) (14) (15) . Pineda et al. (16) did not find an increased risk for gastrointestinal bleeding as either the first cirrhotic decompensation or cause of death in patients who were co-infected with HIV and hepatitis C. Overt coagulopathy alone cannot explain the increased rate of complications that we observed in patients with hepatitis C/HIV co-infection, because biopsies were not performed on patients with abnormal international normalized ratio and partial thromboplastin times. The data, however, do suggest platelet count, and traditional measures of coagulation may not fully define the risk for bleeding in this patient group.
A possible explanation for our observations is that hepatitis C/HIV co-infection may result in subclinical liver disease, with impaired hemostasis that manifests only after the biopsy of an organ with high vascularity such as the kidney. Unfortunately, we do not have liver biopsy data to support this contention. Moreover, the mechanism of impaired hemostasis may not necessarily involve the liver. It is conceivable that hepatitis C/HIV co-infection may alter endothelial-platelet interactions, thereby limiting an effective response to vascular injury. Other factors that predispose to a greater biopsy complication rate may include greater illicit drug and alcohol exposure in the hepatitis C/HIV co-infected population (17) . The limited number of complications and lack of biopsy data on the underlying severity of liver disease do not allow for adequate study of this issue in the current cohort. Comparison of HIV-infected with and without hepatitis C revealed only a difference in age and illicit drug use. These factors are unlikely to explain an in- Figure 1 . Risk for any complication associated with hepatitis C or prebiopsy hematocrit Ͻ30%, stratified by HIV status. Hct, hematocrit. creased bleeding risk. Further studies are required to investigate the mechanism of increased bleeding risk.
Although the risk for complication in the entire cohort increased with every 10,000-cells/mm 3 decrease in the prebiopsy platelet count, inclusion of this variable in a multivariable adjustment model did not alter the association of hepatitis C. As such, the effect of hepatitis C positivity on the risk for bleeding complications likely cannot be explained by platelet count alone.
Our study also found that a prebiopsy hematocrit Ͻ30% was associated with an increased risk for major complication in the cohort as a whole. On further analysis, the risk for any complication associated with hematocrit Ͻ30% was limited to the HIV-positive individuals, although both HIV-positive and -negative patients had an increased risk for major complication. Although a low hematocrit may simply reflect a lower clinical threshold for transfusing these patients, the observation is consistent with multiple previous studies that showed a low preprocedure hematocrit, particularly Ͻ30%, worsens bleeding in surgical patients with uremia and that blood transfusions can help correct that bleeding risk (18 -21) . Although most patients in this study did not have overt uremia, chronic kidney disease-related anemia may alter their hemostatic phenotype (22) . In fact, the median eGFR of the HIV-infected patients was lower than that of the HIV-negative patients, and low hematocrit was associated with greater risk in the HIV-infected patients as compared with the uninfected.
Hematocrit Ͻ30% and eGFR Ͻ30 ml/min per 1.73 m 2 were associated with protection from minor complication but an increased risk for major complication. An explanation for these findings is that patients with a lower hematocrit or more advanced renal dysfunction tend to have greater comorbidities, and if such a patient has a complication, then it may have a tendency to be more severe. Conversely, patients with a hematocrit Ն30% or eGFR Ն30 ml/min per 1.73 m 2 may tend to have less severe complications, again reflecting their better overall health status.
Importantly, the diversity of pathologic diagnoses confirms that kidney biopsy remains an essential tool for accurately diagnosing the cause of renal disease in this population (Table  5 ). Only 29% of the group had HIV-associated nephropathy manifested as collapsing FSGS, with an additional 8% having HIV-related immune complex glomerulonephritis. It is interesting that interstitial nephritis was common at 11%. This high prevalence reflects the difficulty in making this diagnosis on clinical features alone, because consistent, "classical" findings of fever, rash, and eosinophilia are often absent (23) .
This study has several limitations. First, the study population may not be generalizable to all HIV-infected patients. HIVinfected patients in this study were drawn from an urban inner-city population where the major route for HIV infection is injection drug use. Second, specific data on the exact number of needle passes and differences in operator technique were not readily available. Technical differences, however, were accounted for in part by the calculation of robust variances that were based on the attending of record. Third, rates of minor complication may be underreported because kidneys are not routinely reimaged after biopsy unless clinical circumstances warrant. Fourth, the relatively small number of complications in the subset of HIV-infected patients limits the power of this study to identify associations with specific predictors. Fifth, hepatitis C status was imputed for 11.9% of the HIV-negative patients, although sensitivity analyses demonstrated the results to be qualitatively similar. Finally, a definitive mechanism for the increased complication rate in hepatitis C/HIV co-infected patients cannot be answered with certainty from this study.
Conclusions
This study demonstrates that ultrasound-guided percutaneous kidney biopsy remains a relatively safe, well-tolerated procedure in HIV-infected patients. Patients with hepatitis C/HIV co-infection are at greatest risk for biopsy-related complications.
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